Operating characteristics are needed to properly evaluate the scientific validity of phase I protocols

A benchmark for dose-finding studies with unknown ordering

(2020) Pavel Mozgunov et al.   BIOSTATISTICS

Designing and evaluating dose-escalation studies made easy: The MoDEsT web app

(2019) Philip Pallmann et al.   Clinical Trials

A web tool for designing and conducting phase I trials using the continual reassessment method

(2018) Nolan A. Wages et al.   BMC CANCER

The Impact of Early-Phase Trial Design in the Drug Development Process

(2018) Mark R. Conaway et al.   CLINICAL CANCER RESEARCH

Dose-finding designs for trials of molecularly targeted agents and immunotherapies

(2017) Cody Chiuzan et al.   Journal of Biopharmaceutical Statistics

Phase 1 Trial Design: Is 3 + 3 the Best?

(2017) Aaron R. Hansen et al.   Cancer Control

The ASA's Statement onp-Values: Context, Process, and Purpose

(2016) Ronald L. Wasserstein et al.   AMERICAN STATISTICIAN

Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies

(2016) N. A. Wages et al.   ANNALS OF ONCOLOGY

Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials

(2016) Y. Yuan et al.   CLINICAL CANCER RESEARCH

Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy

(2016) L. Nie et al.   CLINICAL CANCER RESEARCH

AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials

(2016) Graham M. Wheeler et al.   PLoS One

Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials

(2015) X. Paoletti et al.   ANNALS OF ONCOLOGY

Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?

(2015) Alexia Iasonos et al.   JOURNAL OF CLINICAL ONCOLOGY

Simple benchmark for complex dose finding studies

(2014) Ying Kuen Cheung   BIOMETRICS

Adaptive Dose-Finding Studies: A Review of Model-Guided Phase I Clinical Trials

(2014) Alexia Iasonos et al.   JOURNAL OF CLINICAL ONCOLOGY

Calibration of prior variance in the Bayesian continual reassessment method

(2011) Shing M. Lee et al.   STATISTICS IN MEDICINE

Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee

(2010) S. P. Ivy et al.   CLINICAL CANCER RESEARCH

Model calibration in the continual reassessment method

(2009) Shing M Lee et al.   Clinical Trials

Dose Escalation Methods in Phase I Cancer Clinical Trials

(2009) Christophe Le Tourneau et al.   JNCI-Journal of the National Cancer Institute

A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies

(2008) Alexia Iasonos et al.   Clinical Trials

Range and trend of expected toxicity level (ETL) in standard A+B designs: A report from the children's oncology group

(2008) Zhengjia Chen et al.   Contemporary Clinical Trials